The Other Shoe Drops: Gilead’s Outrageous Pricing Of Remdesivir

This is an unreasonable price for a drug that has demonstrated little to no ability to save lives or lower viral loads in patients.

Read the full post on Forbes - Healthcare

William A. Haseltine, Contributor